This Sources Sought opportunity from Department Of Defense was posted on May 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
SIR Y90 Microspheres
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Department of Defense, through the Health Readiness Contracting Office at Womack Army Medical Center in Fort Bragg, North Carolina, has issued a Request for Information (RFI) and Sources Sought Notice to gather information for planning a potential sole source contract with Sirtex Medical Inc. This contract intends to procure SIR-Spheres® Y-90 resin microspheres and related materials, which are specialized medical products used in the treatment of unresectable metastatic liver tumors originating from primary colorectal cancer. These microspheres are utilized alongside adjuvant intra-hepatic artery chemotherapy (IHAC) of Floxuridine (FUDR). The notice emphasizes that Sirtex Medical Inc. is the sole provider of these unique medical devices, with no alternative suppliers currently available. This notice is solely for informational purposes and does not obligate the government to any payments for submission costs or require responses for future solicitations. The solicitation number is W91YTZ27QA0011, and the awarding instrument will be a DD Form 1449 for commercial items under the NAICS code 334517, which covers Irradiation Apparatus Manufacturing. Interested parties capable of supplying the specified product are invited to respond to the point of contact, Frank Fogg, by the deadline of May 27, 2026, providing company information including contact details, socio-economic classification, DUNS number, and CAGE code. Telephonic inquiries will not be entertained, and failure to respond does not eliminate the opportunity to participate in any future solicitations related to this requirement.
General Info
Agency
NAICS
Place of Performance
Fort Bragg, NC, 28310, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
This is a Request for Information (RFI) – Sources Sought Notice Only. This notice is issued solely for information and planning purposes only.
The US Government will not pay for any information or administrative costs incurred in response to this notice. Submittals will not be returned to the responder; not responding to this notice does not preclude participation in any further RFQ; IFB or RFP if issued.
Health Readiness Contracting Office -(HRCO), Womack Army Medical Center (WAMC), Fort Bragg, NC 28310, intends to solicit, negotiate, and award a sole sourced contract to Sirtex Medical Inc. 300 Unicorn Park Drive Woburn, MA 01801, United States.
Sirtex Medical Inc will provide SIR-Spheres® Y-90 resin microspheres and other materials used in conjunction with the microspheres. SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Additionally, there are no other companies or firms that sells or distribute such items.
The solicitation number is W91YTZ27QA0011, and the resulting award will be made on DD Form 1449 (Order for Commercial Items). This requirement is for commercial supply for the Department of Nuclear Medicine. The NAICS for this requirement is 334517- Irradiation Apparatus Manufacturing, and Product Service Code (PSC)- Q527 Medical- Nuclear Medicine. The point of contact for this requirement is Frank Fogg frank.a.fogg.civ@health.mil. The Contracting Officer is Amush Collins at anush.m.collins.civ@army.mil.
Your email response shall provide the following:
Can you provide supply the following supply:
Sirtex Medical Inc will provide SIR-Spheres® Y-90 resin microspheres and other materials used in conjunction with the microspheres. SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Additionally, there are no other companies or firms that sells or distribute such items.
If your company can offer this supply item please respond via e-mail to the POC with:
Name of Company
Point of contact
Phone number
Email address
Identify Your Small Business Socio-Economic Group
DUNS number and CAGE Code
No telephonic inquiries will be responded to
